John Migas, MD
Medical Oncology · Normal, ILNPI 1629076971
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,600 of the $2,595 with a category attached, or 61.7%. Pfizer accounts for 67.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $1,623 and has fallen 92.0% since, to $130 in 2025.
Across 54 payments — averaging $48.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Johnson & Johnson$149
- Astellas Pharma US Inc$95
- Novartis$94
- Genentech USA, Inc.$84
- AbbVie$51
- plus $375 from 14 others
Across 220 payments — averaging $1015.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$84K
- Incyte Corporation$76K
- Astrazeneca UK Limited$32K
- Pharmacyclics LLC, An Abbvie Company$15K
- Jazz Pharmaceuticals Inc.$12K
- Novartis$3K
What the payments were for
- Speaking & faculty fees$1,60062%
- Food & beverage$87334%
- Education$1225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $1,748 |
| Johnson & Johnson | 4 | $149 |
| Astellas Pharma US Inc | 5 | $95 |
| Novartis | 4 | $94 |
| Genentech USA, Inc. | 5 | $84 |
| AbbVie | 2 | $51 |
| Eisai Inc. | 2 | $46 |
| Bristol Myers Squibb | 2 | $46 |
| Sanofi | 2 | $42 |
| Taiho Oncology, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Amgen | 1 | $29 |
| Seagen Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| GSK | 1 | $17 |
| Array Biopharma Inc | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$1,600
How this compares
$2,595 in reported general payments places this provider in the 60th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $414,570 |
| EliquisApixaban | 34 | $19,033 |
| Anastrozole | 417 | $7,068 |
| Letrozole | 226 | $3,941 |
| Tamoxifen Citrate | 22 | $655 |
| Ondansetron OdtOndansetron | 16 | $245 |
| Dexamethasone | 20 | $213 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $193 |
| Escitalopram Oxalate | 15 | $66 |
| Hydroxyurea | 16 | $45 |
| Prednisone | 15 | $28 |
| Penicillin V Potassium | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $1,748 | $433,60354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Normal
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Nicklas PfanzelterGlenview$199K
- Jyoti PatelChicago$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.